Home > Browse Reports > Medical Devices > Disposable Syringe Markets

Report Description

Disposable Syringe Markets
Publication Date: 01-OCT-09
Pages: 239
Study: TMRDSM
Format/Price: PDF document / $3,400.00
   


Description:



View Sample PDF


This TriMark Publications report examines the disposable syringe markets as well as the supplies utilized in clinics and by patients directly in their homes to diagnose and monitor disease and to administer medications. This analysis is intended to provide basic market data pertaining to the U.S. and worldwide market segments. Each market segment is analyzed to determine size, growth rates, sales projections and factors influencing growth in the U.S. and internationally. Unit and dollar volume are used to indicate market sizes. Additionally, this review examines industry challenges and potential threats to syringe and needle supplies manufacturers and makes strategic recommendations for boosting market share. The emphasis is on those companies actively developing and marketing products to hospitals, physicians and the general public for medically related uses. The disposable syringe market segments are identified as: 1) total reusable needle and syringe market; 2) total disposable needle and syringe market; 3) prefilled syringes; 4) safety syringes; 5) insulin injector pens; 6) needleless injectors; 7) vaccination injectors; 8) blood collection needles and syringes; 9) hypodermic needles and syringes market; 10) insulin needles and syringes market; 11) specialty needles and syringes market; and 12) needleless injector market.





Table of Contents:

  1. 1. Introduction 11
  2. 1.1 Statement of Report 11
  3. 1.2 About this Report 11
  4. 1.3 Scope of the Report 11
  5. 1.4 Objectives 12
  6. 1.5 Methodology 13
  7. 1.6 Executive Summary 14
  8. 2. Disposable Syringe Markets 16
  9. 2.1 Overview 16
  10. 2.2 Infection Control and Safety 17
  11. 2.2.1 Needlestick Injuries 17
  12. 2.2.2 Availability of Safety Syringes in the U.S. Healthcare Facilities 19
  13. 2.3 Cost of Safety Syringe 19
  14. 2.4 Market Expansion 20
  15. 2.5 Unsafe Injection Practices 20
  16. 2.6 Hospital Consolidations Pressure Companies to Reduce Prices 20
  17. 2.7 Strategic Alliance of Needleless Injector Manufacturers 21
  18. 2.8 Technological Advancements in Disposable Syringes 21
  19. 2.8.1 Reconstitution inside Sterile Syringes 21
  20. 2.8.2 Plungerless Prefilled Syringes 22
  21. 2.8.3 The Disposable UniJect™ 22
  22. 2.9 Award Winning Syringes 22
  23. 2.9.1 Episure AutoDetect Epidural Syringe 23
  24. 2.9.2 ConfiDose Disposable Autoinjector 23
  25. 2.9.3 Humatrope Reconstitution Device 24
  26. 2.9.4 Vasceze Plungerless Syringe 24
  27. 3. Disposable Syringe Market Segments 25
  28. 3.1 Overview 25
  29. 3.1.1 World Market for Disposable Syringes 25
  30. 3.1.2 U.S. Market for Disposable Syringes 27
  31. 3.1.3 Disposable Syringe Market in India 29
  32. 4. Insulin Syringes 32
  33. 4.1 Insulin Strengths: U-40 and U-100 32
  34. 4.2 Market for Insulin Pen 33
  35. 4.3 Shelf Life of Insulin Pen Cartridges 34
  36. 4.4 An Update on Insulin Injection Devices 35
  37. 4.4.1 Insulin Injection Devices Currently Available in the U.S. 35
  38. 4.4.2 Disposable Pens 36
  39. 4.4.3 Refillable Pens 36
  40. 4.4.4 Pen Needles 36
  41. 4.4.5 Benefits and Patient Preferences 37
  42. 4.4.6 Disadvantages of Pen Syringes 37
  43. 4.4.7 Insulin Pens and the Hospital Bills 38
  44. 4.5 Insulin Pens for Indian Market from IDC 38
  45. 4.6 Expansion of Facilities for Insulin Pens by Eli Lilly and Rexam 39
  46. 4.7 Major Players in Insulin Pens and Syringes 39
  47. 4.7.1 Sanofi-Aventis 39
  48. 4.7.1.1 Sanofi-Aventis' Business in Diabetes Care Segment 39
  49. 4.7.2 Novo Nordisk 41
  50. 4.7.2.1 Novo Nordisk's Diabetes Care Business in North America 41
  51. 4.7.2.2 Novo Nordisk's International Operations 42
  52. 4.7.2.3 Novo Nordisk's Business in Diabetes Care in Europe 42
  53. 4.7.3 Eli Lilly & Co. 43
  54. 4.7.3.1 Byetta 43
  55. 4.7.3.2 Humulin 44
  56. 4.7.3.3 Humalog 45
  57. 5. Safety Syringes 46
  58. 5.1 Available Safety Syringe Technologies 46
  59. 5.1.1 Retrofitted Syringes 46
  60. 5.1.2 Automatically Retractable Syringes 46
  61. 5.1.3 Manually Retractable Syringes 46
  62. 5.2 Safety Syringe Market 47
  63. 5.3 Drivers of Safety Syringes 47
  64. 6. Prefilled Syringes 48
  65. 6.1 Types of Prefilled Syringes (PFS) 48
  66. 6.2 Market for Prefilled Syringes 48
  67. 6.3 The Rise of Prefilled Syringes 49
  68. 6.4 Needle Safety for Prefilled Syringes 50
  69. 6.4.1 V-OVS NS® 51
  70. 6.4.2 Preventis™ 51
  71. 6.4.3 UltraSafe Passive® Delivery System/ERYPROSafe™ and NUFILSafe™ 51
  72. 6.5 Sterility Maintenance of Prefilled Syringes 52
  73. 6.6 Compatibility of Drugs with the Components of Prefilled Syringes 52
  74. 6.7 Some of the Drugs Available in Prefilled Syringes 53
  75. 6.7.1 Ovidrel® PreFilled Syringe 53
  76. 6.7.2 Enbrel Prefilled Syringes 53
  77. 6.7.3 Biocon's Prefilled Safety Syringes 53
  78. 6.7.4 Relistor® Prefilled Syringes 54
  79. 6.7.5 PEGASYS® 54
  80. 6.7.6 Afluria® 54
  81. 6.7.7 Enzira® 55
  82. 6.7.8 FluZone® Prefilled Syringe for Children 55
  83. 6.7.9 Novolin® N FlexPen Prefilled Insulin Syringe 55
  84. 6.7.10 NovoLog® Insulin Prefilled Syringe 55
  85. 6.7.11 GlaxoSmithKline's Vaccines in Prefilled Syringes 56
  86. 6.8 U.S. Production of Unilife's Prefilled Syringes 56
  87. 6.9 Some of the Major Providers of Syringe-Prefilling Services and Products 57
  88. 6.9.1 Althea Technologies, Inc. 57
  89. 6.9.1.1 Althea's Clinical Manufacturing 57
  90. 6.9.1.2 Althea's Fill/Finish Services 58
  91. 6.9.1.3 Althea's Contract Manufacturing 58
  92. 6.9.2 Baxter International, Inc. 59
  93. 6.9.2.1 Baxter's Contract Manufacturing 60
  94. 6.9.2.2 Baxter's Fill and Finish Capabilities 60
  95. 6.9.2.3 Baxter's Prefilled Syringes Capability 60
  96. 6.9.2.4 Baxter's Vials 61
  97. 6.9.2.5 Baxter's Cartridges 61
  98. 6.9.3 Becton, Dickinson and Company 61
  99. 6.9.3.1 BD's Prefilled Syringe Services 62
  100. 6.9.3.2 BD Hypak SCF™ Glass Prefillable Syringes 62
  101. 6.9.3.3 BD Sterifill SCF™ Plastic Prefillable Syringe Systems 63
  102. 6.9.3.4 BD Physioject™ Disposable AutoInjector 63
  103. 6.9.3.5 BD™ MicroInfusor™ Automatic Injection System 64
  104. 6.9.3.6 BD™ Liquid Dry Injector Disposable Pen Injector 64
  105. 6.9.3.7 BD™ Pens Customized Self-Injection Systems 65
  106. 6.9.3.8 BD Soluvia™ Prefillable Microinjection System 65
  107. 6.9.3.9 BD Preventis™ Shielding System for Prefilled Syringes 66
  108. 6.9.4 Catalent Pharma Solutions, Inc. 68
  109. 6.9.4.1 The Protector Safety Shield System™ 69
  110. 6.9.4.2 The ASI™ Autoinjector and Ultra-Compact ASI Mini™ Autoinjector 69
  111. 6.9.5 Hyaluron Contract Manufacturing (HCM) 69
  112. 6.9.5.1 Hyaluron's Syringe Filling 69
  113. 6.9.6 Vetter Pharma Fertigung GmbH 70
  114. 6.10 Features of Prefilled Syringes 71
  115. 6.10.1 Dual Chamber Prefilled Syringes 71
  116. 7. Pen Syringes 72
  117. 7.1 Pen Devices for Insulin Delivery 73
  118. 7.2 Technical Advances in Insulin Pens 73
  119. 7.3 Pen Types and Styles 74
  120. 7.4 Prefilled Pens 74
  121. 7.5 Reusable Pens 74
  122. 7.6 Prefilled Autoinjecting Disposable Syringes 74
  123. 7.7 Uniject™ Injection Device 75
  124. 8. Microneedle 76
  125. 8.1 Electronic Mosquito 76
  126. 9. Needle-free Injectors 77
  127. 9.1 Needle-free Delivery of Liquids 77
  128. 9.2 Needle-free Delivery of Solid Formulations 78
  129. 9.3 Needleless Injector from Injex 79
  130. 9.4 Jet Syringe from Injex 79
  131. 9.5 Syrijet 79
  132. 9.6 PenJet 80
  133. 9.7 Needle-free Injector for Human Growth Hormone 80
  134. 10. Needle and Syringe Market Trends 81
  135. 10.1 Market Segments 81
  136. 10.2 Customer Needs 82
  137. 10.3 Competitor Analysis 82
  138. 10.3.1 Automatic Safety Syringes 82
  139. 10.3.2 Manually Locking Safety Syringes 83
  140. 10.4 Third Party Reimbursement 84
  141. 10.5 Regulation 84
  142. 10.6 Drug Discovery Trends 85
  143. 10.7 Demographic Shifts 85
  144. 10.8 Growth in Home Healthcare 85
  145. 11. Technological Developments 87
  146. 11.1 Auto-Disable Syringes 87
  147. 11.1.1 AD Syringes with Needle Retraction/Disposal Feature 88
  148. 11.1.2 AD Syringe with No Needle Retraction Feature 88
  149. 11.1.3 Needlestick Prevention Syringes 88
  150. 11.1.4 Automatic Needlestick Prevention Feature 89
  151. 11.1.4.1 UltraSafe®Passive™ Delivery System 89
  152. 11.1.4.2 Sterimatic Sleeve® 89
  153. 11.1.4.3 K3 Safety Cap 89
  154. 11.2 Manual Needlestick Prevention Feature 90
  155. 11.2.1 Safety Lok™ Syringe 90
  156. 11.2.2 Monoject®Magellan™ 90
  157. 12. Business Trends 91
  158. 12.1 Market Drivers 91
  159. 12.2 Market Prospects 92
  160. 12.3 Marketing and Distribution 93
  161. 12.4 Competitive Landscape 93
  162. 12.5 Future Technologies 94
  163. 12.5.1 Glide Solid Dose Injector (SDI™) 94
  164. 12.5.2 BD Physioject™ 94
  165. 13. Regulatory Measures 95
  166. 13.1 Safety Syringes in Europe 95
  167. 14. Company Profiles 96
  168. 14.1 Abbott Laboratories 96
  169. 14.1.1 HUMIRA® Prefilled Syringe 96
  170. 14.1.2 HUMIRA® Pen 97
  171. 14.1.3 Precision Sure-Dose® Insulin Syringes 97
  172. 14.2 Albert David Limited 98
  173. 14.3 Alshifa Medical Syringes Manufacturing Company Ltd. 99
  174. 14.4 Althea Technologies, Inc. 99
  175. 14.5 Avitro, Inc. 100
  176. 14.6 Baxter International, Inc. 100
  177. 14.6.1 Baxter's Medication Delivery 100
  178. 14.6.2 Baxter's IV Therapies 101
  179. 14.6.3 Baxter's Global Injectables 101
  180. 14.6.4 Baxter's Infusion Systems 102
  181. 14.6.5 Baxter's IV Infusion Pumps and Infusion Sets 103
  182. 14.6.6 Baxter's Pharma Partnering 103
  183. 14.7 Becton, Dickinson and Company (BD) 103
  184. 14.7.1 BD's Role in Designing Devices for Safe and Effective Injections and Infusions 103
  185. 14.7.2 BD's Products 103
  186. 14.8 Boston Scientific Corporation 113
  187. 14.9 B. Braun 113
  188. 14.9.1 The Hospital Care Division 113
  189. 14.9.2 The Aesculap Division 114
  190. 14.9.3 The Out Patient Market (OPM) Division 114
  191. 14.9.4 The B. Braun Avitum Division 115
  192. 14.9.5 B. Braun's Syringe Products 116
  193. 14.10 Bioject Medical Technologies, Inc. 122
  194. 14.10.1 Biojector® 2000 124
  195. 14.10.2 Drug Reconstitution System 125
  196. 14.10.3 Vitajet® 125
  197. 14.10.4 Cool.click™ 125
  198. 14.10.5 SeroJet™ 126
  199. 14.11 Catalent Pharma Solutions, Inc. 126
  200. 14.11.1 Catalent's Oral Technologies Segment 127
  201. 14.11.2 Catalent's Sterile Technologies Segment 128
  202. 14.11.3 Catalent's Packaging Services Segment 129
  203. 14.11.4 Catalent's Manufacturing Capabilities 130
  204. 14.11.5 Catalent's Employee Strength 130
  205. 14.11.6 Catalent's Syringes 131
  206. 14.12 C.R. Bard, Inc. 131
  207. 14.12.1 Bard's Vascular Business 131
  208. 14.12.2 Bard's Urology Business 132
  209. 14.12.3 Bard's Oncology Business 133
  210. 14.12.4 Bard's Business in Surgical Specialties 134
  211. 14.12.5 Bard's Overseas Expansion 134
  212. 14.12.6 Bard's Bulb Syringes and Trays 135
  213. 14.12.7 Bard's Piston Syringes and Trays 135
  214. 14.13 Coeur, Inc. 136
  215. 14.13.1 Angiographic Syringes from Coeur, Inc. 136
  216. 14.13.2 CT Syringes from Coeur, Inc. 137
  217. 14.14 Covidien Ltd. 137
  218. 14.14.1 Covidien's Medical Devices Segment 138
  219. 14.14.2 Covidien's R&D 139
  220. 14.14.3 Covidien's Competitors in Medical Devices 139
  221. 14.14.4 Covidien's Syringes 140
  222. 14.15 Henke-Sass, Wolf GmbH 144
  223. 14.15.1 Two-Part Disposable Syringes 1-50(60) ml 144
  224. 14.15.2 Three-Part Disposable Syringes 1-30 ml 144
  225. 14.15.3 Disposable Needles HSW FINE-JECT® 145
  226. 14.16 Hindustan Syringes & Medical Devices, Ltd. (HMD) 145
  227. 14.16.1 Insulin Syringes from HMD 145
  228. 14.16.2 HMD's Single Use Needles 146
  229. 14.16.3 HMD's Single Use Syringes 147
  230. 14.17 Hi-Tech Medical Products Ltd. 147
  231. 14.18 Hyaluron Contract Manufacturing 148
  232. 14.18.1 HCM's Major Markets 148
  233. 14.18.2 HCM's Facility 148
  234. 14.19 International Medication System Ltd. 149
  235. 14.19.1 Delivery Systems from IMS 149
  236. 14.19.2 PCA Products from IMS 151
  237. 14.19.3 Phytonadione Injection USP 151
  238. 14.19.4 Lidocaine HCl Jelly, USP 2% (Preservative-free) 152
  239. 14.20 Life-Shield Products, Inc. 152
  240. 14.21 Merit Medical Systems, Inc. 154
  241. 14.21.1 Merit's Products 154
  242. 14.21.2 Merit's Vascular Access Products 154
  243. 14.21.3 Merit's Business in the U.S. 155
  244. 14.21.4 Merit's International Business 156
  245. 14.21.5 Merit's Customers 156
  246. 14.21.6 Merit's R&D 156
  247. 14.21.7 Merit's Manufacturing Facilities 157
  248. 14.22 Milestone Scientific 157
  249. 14.22.1 Milestone Scientific's Product Platform 158
  250. 14.22.2 Milestone Scientific's Investment in R&D 159
  251. 14.22.3 Milestone Scientific's Business Performance 160
  252. 14.23 Novo Nordisk A/S 161
  253. 14.23.1 Novo Nordisk's Business in Diabetes Care Segment 161
  254. 14.23.2 Novo Nordisk's Modern Insulins, Human Insulins and Insulin-related Products 162
  255. 14.23.3 Novo Nordisk's Geographic Performance in Diabetes Care Products 163
  256. 14.23.4 Pipeline Progress in Nova Nordisk 163
  257. 14.23.5 Novo Nordisk's Modern Insulin Portfolio 164
  258. 14.24 Owen Mumford Ltd. 166
  259. 14.24.1 Owen Mumford's Global Locations 166
  260. 14.24.2 Owen Mumford's Products 168
  261. 14.25 Plas-Pak Industries, Inc. 170
  262. 14.25.1 Dial-A-Dose® Disposable Veterinary Syringes 170
  263. 14.25.2 Dual Syringe and Dental Syringe from Plas-Pak 170
  264. 14.25.3 Mini Dual Syringe 170
  265. 14.25.4 Manual Dual Syringes 171
  266. 14.26 Retractable Technologies, Inc. 172
  267. 14.26.1 Retractable Technologies' Principal Products 173
  268. 14.26.2 Retractable Technologies' Principal Markets 173
  269. 14.26.3 Retractable Technologies' R&D 174
  270. 14.26.4 Retractable Technologies' VanishPoint Products 175
  271. 14.27 Revolutions Medical Corporation 176
  272. 14.27.1 Rev Vac Safety Syringe 177
  273. 14.28 Safety Syringes, Inc. 177
  274. 14.28.1 Custom Engineering from Safety Syringes, Inc. 178
  275. 14.28.2 Syringe Products from Safety Syringes, Inc. 178
  276. 14.29 Smiths Medical International/Medex, Inc. 180
  277. 14.29.1 Smiths Medical's Markets 180
  278. 14.29.2 Smiths Medical's Medication Delivery Segment 181
  279. 14.29.3 Smiths Medical's Vital Care Segment 182
  280. 14.29.4 Smiths Medical's Safety Devices Segment 182
  281. 14.29.5 Smiths Medical's Business Performance 182
  282. 14.29.6 Smiths Medical's Business Performance on Geographic Basis 182
  283. 14.29.7 Smiths Medical's R&D 183
  284. 14.29.8 Syringes from Smiths Medicals 183
  285. 14.30 Specialized Health Products International, Inc. 188
  286. 14.30.1 SHPI's Products and Services 189
  287. 14.30.2 SHPI's Licensed Products 190
  288. 14.31 Star Syringe Ltd. 190
  289. 14.31.1 Star Alliances 191
  290. 14.31.2 Preoducts from Star Syringe Ltd. 192
  291. 14.32 Terumo's Medical Corporation 193
  292. 14.32.1 Terumo's General Hospital Products 193
  293. 14.32.2 Terumo's Diabetes Care Products 194
  294. 14.32.3 Terumo's Syringe Products 195
  295. 14.33 UltiMed, Inc. 203
  296. 14.33.1 UltiCare™ Insulin Syringes 204
  297. 14.33.2 UltiCare™ Pen Needles 204
  298. 14.34 Unilife Medical Solutions, Ltd. 205
  299. 14.34.1 Pharmaceutical Market for Unilife's Prefilled Syringes 205
  300. 14.34.2 Unilife Partnership with Sanofi-Aventis 205
  301. 14.34.3 Unilife's Licensing Agreement with Sanofi-Aventis 206
  302. 14.34.4 Unilife's Partnership with Gerresheimer Bünde 206
  303. 14.34.5 Unilife's Portfolio of Safety Syringes 207
  304. 14.34.6 Unilife's Prefilled Syringes 207
  305. 14.34.7 Unilife's Contract Manufacturing Activities 207
  306. 14.34.8 Unilife's Performance in Syringe Market 208
  307. 14.35 Vetter Pharma-Fertigung GmbH & Co., KG 208
  308. 14.35.1 Vetter Services and Solutions 208
  309. 14.35.2 Dual-Chamber Technology 209
  310. 14.36 Vita Needle Company, Inc. 209
  311. 14.36.1 Disposable Stainless Steel Needle Blunts from Vita Needle 209
  312. 14.36.2 Teflon® Dispensing Needles 210
  313. 14.36.3 Vita Needle's Polypropylene Needles 210
  314. 14.36.4 Vita Needle's Taper Tip Needles 211
  315. 14.37 West Pharmaceutical Services, Inc. 211
  316. 14.37.1 West's Pharmaceutical Systems Segment 211
  317. 14.37.2 West's Tech Group Segment 212
  318. 14.37.3 West's R&D Activities 213
  319. 14.37.4 West's Syringe Products 214
  320. 14.38 Wuxi Yushou Medical Appliances Co., Ltd. 217
  321. 14.39 Ypsomed Holding AG 217
  322. 14.39.1 Ypsomed's Injection Systems 218
  323. 14.39.2 Ypsomed's Insulin Delivery Systems 218
  324. 14.39.3 Additional Indication Areas for Pen Systems 218
  325. 14.39.4 Ypsomed's Innovative Injection Systems at a Glance 219
  326. 14.39.5 Ypsomed's Complete Product Range for Insulin Suppliers 219
  327. 14.39.6 Ypsomed's New Dual-Chamber Injecting Systems 220
  328. 14.39.7 Ypsomed's ServoPen 220
  329. 14.39.8 Growth of Ypsomed's Pen Needles 220
  330. 14.39.9 Ypsomed's Performance in 2008/2009 222
  331. 14.39.10 Ypsomed's R&D 223
  332. 14.40 The Medical House PLC (TMH) 224
  333. 14.40.1 TMH's Products 224
  334. Appendix 1: U.S. Healthcare Expenditure Projections, 2008-2018 228
  335. Appendix 2: Syringe Needle Terminology 234
  336. Appendix 3: Medication Errors and Syringe Safety 236
  337. Appendix 3.1: Injectable Medication Errors 236
  338. Appendix 3.2: Frequency of Syringe Usage 236
  339. Appendix 3.3: Labeling Injectable Medications 236
  340. Appendix 3.4: Challenges of Labeling 236
  341. Appendix 3.5: Benefits of a Write-On Stripe 236
  342. Appendix 3.6: Nurses Influence on Selection of Sharp Devices 237
  343. Appendix 3.7: Needlestick Injuries 237
  344. Appendix 3.8: Prevention of Needlestick Injuries 237
  345. Appendix 3.9: Protection from Needlestick Injuries 238
  346. INDEX OF FIGURES
  347. Figure 2.1: Principal Causes of Needlestick Injuries 17
  348. Figure 2.2: Availability of Safety Syringes in the U.S. Healthcare Facilities, 2008 19
  349. Figure 3.1: Worldwide Unit Market for Syringes and Needles, 2004-2012 26
  350. Figure 3.2: Global Syringe Market, 2009 26
  351. Figure 3.3: Worldwide Market for Disposable Syringes and Needles, 2004-2012 27
  352. Figure 3.4: U.S. Market for Disposable Syringes and Needles, 2006-2013 28
  353. Figure 3.5: Market Segments of the U.S. Syringe Market, 2009 28
  354. Figure 3.6: E.U. Market for Syringes, Needles and Catheters, 2007 and 2008 29
  355. Figure 3.7: Worldwide Market Share for Hypodermic Syringes, 2009 29
  356. Figure 3.8: Disposable Syringe Market in India, 2008-2012 30
  357. Figure 3.9: Market Share for Disposable Syringes in India, 2008 30
  358. Figure 3.10: Market Share for Disposable Needles in India, 2008 31
  359. Figure 4.1: Market Growth for Insulin Pen, 2007-2014 33
  360. Figure 4.2: Market Growth for Insulin Pens in Europe, 2007-2014 34
  361. Figure 4.3: Global Sales Performance of Sanofi-Aventis' Lantus, 2007 and 2008 40
  362. Figure 4.4: Global Sales Performance of Sanofi-Aventis' Amaryl, 2007 and 2008 40
  363. Figure 4.5: Sales Performance of Sanofi-Aventis' Lantus by Geography, 2008 41
  364. Figure 4.6: Novo Nordisk's Business Performance in Diabetes Care by Geography, 2008 41
  365. Figure 4.7: Novo Nordisk's Performance in Diabetes Care, 2004-2008 42
  366. Figure 4.8: Eli Lilly's Business Performance in Byetta, 2006 and 2007 43
  367. Figure 4.9: Eli Lilly's Business Performance in Humulin, 2006-2008 44
  368. Figure 4.10: Eli Lilly's Sales Performance in Humalog, 2006-2008 45
  369. Figure 5.1: Growth of Safety Syringe Market, 2008-2012 47
  370. Figure 6.1: Market Growth for Prefilled Syringes, 2009-2013 48
  371. Figure 6.2: Growth of Prefilled Syringes Market in E.U., 2008-2012 49
  372. Figure 10.1: Breakdown of U.S. Syringe Market, 2009 81
  373. Figure 10.2: U.S. Home Healthcare Products Market, 2007-2012 85
  374. Figure 14.1: Abbott's Global Business Performance by Country, 2008 96
  375. Figure 14.2: Abbott's Global Business Performance, 2004-2008 98
  376. Figure 14.3: Baxter's Performance in Medication Delivery Segment, 2008 101
  377. Figure 14.4: Baxter's Performance in IV Therapies, 2006-2008 101
  378. Figure 14.5: Baxter's Performance in Injectables, 2006-2008 102
  379. Figure 14.6: Baxter's Performance in Infusion Systems, 2006-2008 102
  380. Figure 14.7: BD's Performance in Safety-engineered Devices, 2007 and 2008 106
  381. Figure 14.8: BD's International Performance in Safety-engineered Devices, 2007 and 2008 106
  382. Figure 14.9: Business Performance by B. Braun's Hospital Care Division, 2006-2008 113
  383. Figure 14.10: Business Performance by B. Braun's Aesculap Division, 2006-2008 114
  384. Figure 14.11: Business Performance by B. Braun's Out Patient Market Division, 2006-2008 115
  385. Figure 14.12: Business Performance by B. Braun's Avitum Division, 2006-2008 115
  386. Figure 14.13: B. Braun's Business Performance by Geographic Region, 2008 116
  387. Figure 14.14: Share of Bioject's Business with its Prominent Customers, 2007 123
  388. Figure 14.15: Bioject's Business Performance by Product Line, 2007 123
  389. Figure 14.16: Biotech's Business Performance in the U.S. and Other Countries, 2007 124
  390. Figure 14.17: Catalent's Business Performance, 2004-2008 127
  391. Figure 14.18: Catalent's Business Performance in its Oral Technologies Segment, 2007 and 2008 128
  392. Figure 14.19: Catalent's Business Performance in its Sterile Technologies Segment, 2007 and 2008 129
  393. Figure 14.20: Catalent's Business Performance in its Packaging Services Segment, 2007 and 2008 130
  394. Figure 14.21: Catalent's Employee Strength by Region, 2008 131
  395. Figure 14.22: Bard's Business Performance in its Vascular Segment, 2004-2008 132
  396. Figure 14.23: Bard's Business Performance in its Urology Segment, 2004-2008 133
  397. Figure 14.24: Bard's Business Performance in its Oncology Segment, 2004-2008 133
  398. Figure 14.25: Bard's Business Performance in its Surgical Specialties Segment, 2004-2008 134
  399. Figure 14.26: Business Performance of Covidien's Medical Device Segment, 2006-2008 138
  400. Figure 14.27: Covidien's Investment in R&D, 2006-2008 139
  401. Figure 14.28: Covidien's Business Performance in Syringes (Sharp Safety Products), 2006-2008 140
  402. Figure 14.29: Merit's Business Performance, 2004-2008 156
  403. Figure 14.30: Merit's Investment in R&D, 2004-2008 157
  404. Figure 14.31: Milestone Scientific's Investment in R&D, 2007 and 2008 160
  405. Figure 14.32: Milestone Scientific's Domestic Business Performance, 2007 and 2008 160
  406. Figure 14.33: Milestone Scientific's International Business Performance, 2007 and 2008 161
  407. Figure 14.34: Novo Nordisk's Sales Performance of Diabetes Care Products, 2004-2008 162
  408. Figure 14.35: Novo Nordisk's Sales Performance in Modern Insulins (Insulin Analogues), 2004-2008 162
  409. Figure 14.36: Retractable Technologies' Business Performance, 2004-2008 173
  410. Figure 14.37: Retractable Technologies' Domestic Business Performance, 2006-2008 174
  411. Figure 14.38: Retractable Technologies' International Business Performance, 2006-2008 174
  412. Figure 14.39: Retractable Technologies' Investment in Research and Expenditure, 2006-2008 175
  413. Figure 14.40: Smiths Medical's Business Performance, 2007 and 2008 181
  414. Figure 14.41: Smiths Medical's Business Performance by Segment, 2007 181
  415. Figure 14.42: SHPI's Sales Performance, 2006 and 2007 188
  416. Figure 14.43: SHPI's Revenue from Royalties, 2006 and 2007 189
  417. Figure 14.44: Terumo's Business Performance in Prefilled Syringes, 2005-2007 194
  418. Figure 14.45: Terumo's Business Performance in Diabetes Care, 2003-2007 94
  419. Figure 14.46: West's Business Performance in Pharmaceutical Systems Segment, 2006-2008 212
  420. Figure 14.47: West's Business Performance in Tech Group Segment, 2006-2008 213
  421. Figure 14.48: West's Investment in R&D in Pharmaceutical Systems Segment, 2006-2008 213
  422. Figure 14.49: West's Investment for R&D in Tech Group Segment, 2006-2008 214
  423. Figure 14.50: Global Prevalence of Diabetes, 2008-2025 220
  424. Figure 14.51: Prevalence of Diabetes in India, 2008-2025 221
  425. Figure 14.52: Prevalence of Diabetes in China, 2008-2025 222
  426. Figure 14.53: Ypsomed's Sales Performance, 2006/2007 and 2008/2009 223
  427. Figure 14.54: Ypsomed's Sales Performance by Geography, 2008/2009 223
  428. Figure 14.55: Ypsomed's R&D Expenditure, 2006/2007 and 2008/2009 224
  429. Figure 14.56: TMH's Business Performance, 2006-2008 226
  430. Figure 14.57: TMH's Business Performance by Geography, 2008 227
  431. Figure A1.1: National Health Expenditure in the U.S., 2009-2014 228
  432. Figure A1.2: National Health Expenditure as a Percent of GDP, 2009-2014 228
  433. Figure A1.3: Health Expenditure Per Capita, 2009-2014 229
  434. Figure A1.4: Home Healthcare Expenditure, 2009-2014 229
  435. Figure A1.5: Prescription Drug Expenditure, 2009-2014 230
  436. Figure A1.6: Other Non-Durable Medical Products Expenditure, 2009-2014 230
  437. Figure A1.7: Nursing Home Care Expenditure, 2009-2014 231
  438. Figure A1.8: Dental Service Expenditure, 2009-2014 231
  439. Figure A1.9: Hospital Care Expenditure, 2009-2014 232
  440. Figure A1.10: Physician and Clinical Services Expenditure, 2009-2014 232
  441. Figure A1.11: Personal Healthcare Expenditure, 2009-2014 233
  442. Figure A3.1: Timing of Needlestick Injuries 237
  443. INDEX OF TABLES
  444. Table 4.1: Shelf Life of Insulin Pen Cartridges 34
  445. Table 4.2: Major Insulin Pen Devices Currently Available in the U.S., 2008 35
  446. Table 10.1: Highlights of Several Leaders in the Disposable Safety Syringe Market 84
  447. Table 14.1: Albert David's Syringes with Needles, 2009 98
  448. Table 14.2: Albert David's Needles, 2009 99
  449. Table 14.3: BD's Auto-Disable Syringes 105
  450. Table 14.4: Insulin Syringes from BD, 2009 107
  451. Table 14.5: BD's Allergy Syringes 107
  452. Table 14.6: BD's Tuberculin Syringes 108
  453. Table 14.7: BD's Syringes and Needles (Sterile, Single-Use) 108
  454. Table 14.8: BD's Safety-Lok™ Safety-Syringes 110
  455. Table 14.9: BD's SafetyGlide Syringes 110
  456. Table 14.10: BD's Eclipse Syringes 111
  457. Table 14.11: BD's Integra Syringes 111
  458. Table 14.12: BD's PosiFlush Prefilled Syringes 112
  459. Table 14.13: Bard's Piston Syringes and Trays, 2009 135
  460. Table 14.14: Bard's Bulb Syringes and Trays, 2009 135
  461. Table 14.15: Angiographic Syringes from Coeur, Inc., 2009 136
  462. Table 14.16: CT Syringes from Coeur, Inc., 2009 137
  463. Table 14.17: HMD's Dispovan Insulin Syringes, 2009 146
  464. Table 14.18: HMD's Single Use Needles, 2009 146
  465. Table 14.19: HMD's Single Use Syringes, 2009 147
  466. Table 14.20: Hi-Tech Single-Use Syringes, 2009 147
  467. Table 14.21: Hi-Tech's Single Use Insulin Syringes, 2009 148
  468. Table 14.22: HCM's Contract Manufacturing Categories, 2009 149
  469. Table 14.23: Syringes from IMS, 2009 150
  470. Table 14.24: PCA Syringe from IMS, 2009 151
  471. Table 14.25: Phytonadione Injection USP from IMS, 2009 151
  472. Table 14.26: Lidocaine Prefilled Syringes from IMS, 2009 152
  473. Table 14.27: Life-Shield's Syringe Products, 2008 153
  474. Table 14.28: Autopen Products from Owen Mumford, 2008 168
  475. Table 14.29: Unifine Products from Owen Mumford, 2008 169
  476. Table 14.30: Autoject Products from Owen Mumford, 2008 169
  477. Table 14.31: Retractable Technologies' VanishPoint Syringes, 2009 176
  478. Table 14.32: Smiths' Pro Fixed Needle TB Syringe, 2009 183
  479. Table 14.33: Smiths' Needle-Pro® Needle with Needle Protection Device 184
  480. Table 14.34: Smiths' Needle-Pro® Syringe and Needle with Needle Protection Device, 2009 186
  481. Table 14.35: Smiths' Needle-Pro® Needle Protection Device for Insulin Injections, 2009 187
  482. Table 14.36: Smiths' Needle-Pro® Fixed Needle Insulin Syringe 187
  483. Table 14.37: SurGard2 Syringes with Safety Needle, 2009 195
  484. Table 14.38: Terumo's SurGuard2 Safety Needles, 2009 196
  485. Table 14.39: Terumo's Hypodermic Needles, 2009 197
  486. Table 14.40: Terumo's Hypodermic Syringes without Needle, 2009 198
  487. Table 14.41: Terumo's Tuberculin Syringes, 2009 199
  488. Table 14.42: Terumo's Hypodermic Syringes with Needle 200
  489. Table 14.43: Terumo's SurSaver 1 cc Syringes with Low Dead Space, 2009 200
  490. Table 14.44: Terumo's Dental Needles, 2009 201
  491. Table 14.45: Terumo's Spinal Needles, 2009 201
  492. Table 14.46: Terumo's SurGuard Safety Insulin Syringes, 2009 202
  493. Table 14.47: Terumo's Insulin Syringes, 2009 203
  494. Table 15.48: Thinpro's Insulin Syringes, 2009 203
  495. Table 15.49: UltiMed's UltiCare Insulin Syringes, 2009 204
  496. Table 14.50: UltiCare Pen Needles, 2009 205
  497. Table 14.51: Vita Needle's Stainless Steel Needle Blunts, 2009 210
  498. Table 14.52: Vita Needle's Teflon Dispensing Needles, 2009 210
  499. Table 14.53: Vita Needle's Polypropylene Needles, 2009 211
  500. Table 14.54: Vita Needle's Taper Tip Needles, 2009 211
  501. Table 14.55: Ypsomed's Product Roadmap, 2009-2013 218
  502. Table 14.56: Ypsomed's Innovative Platforms 219

Registration
Browse Reports
Search TriMark
Reading Room
My Account
View Cart
Home  |  Reports  |  Database Tables  |  Conferences  |  Contact Us  
     © 2008 TriMark Publications, LLC. All rights reserved.